

Defining and Measuring Innovation in a Changing Biomedical Landscape

Washington Plaza Hotel • Washington, DC

October 14, 2015

Participant List

Murray Aitken

Senior Vice President, IMS Health and Executive Director, IMS Institute for Healthcare Informatics

Naomi Aronson

Executive Director, Clinical Evaluation, Innovation and Policy, Office of Clinical Affairs, Blue Cross and Blue Shield Association

Céline Audibert

Director, European Market Research, Deerfield Institute

Marc Berger

Vice President, Real World Data and Analytics, Pfizer

Ernst Berndt

Louis E. Seley Professor in Applied Economics, Sloan School of Management, Massachusetts Institute of Technology

Robert Califf

Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration

Jordan Chapman

Coordinator, Science and Regulatory Affairs, Biotechnology Industry Organization

Rick Chapman

Director of Health Economics, Institute for Clinical and Economic Review

Bill Chin

Executive Vice President, Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Sarina Coates

Research Assistant, Center for Health Policy, The Brookings Institution

Ryan Conrad

Economist, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gregory Daniel

Managing Director, Evidence Development and Innovation, Center for Health Policy and Fellow, Economic Studies, The Brookings Institution

Jennifer Graff

Vice President, Comparative Effectiveness Research, National Pharmaceutical Council

Robert Guidos

Senior Advisor to the Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jonathan Jarow

Acting Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Amber Jessup

Senior Economist, Office of Data Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services

Ken Kaitin

Director, Tufts Center for the Study of Drug Development and Professor, Tufts University School of Medicine

Kirk Kerr

Economist, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Paul Kluetz

Acting Deputy Director, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Michael Lanthier

Operations Research Analyst, Office of Planning, Office of the Commissioner, U.S. Food and Drug Administration

Jonathan Leff

Partner, Deerfield Management and Chairman, Deerfield Institute

Kimberly McCleary

Managing Director, FasterCures

Mark McClellan

Senior Fellow and Director, Health Care Innovation and Value Initiative, The Brookings Institution

Bernard Munos

Innovation Fellow, FasterCures

Bill Murray

President and Chief Executive Officer, Medical Device Innovation Consortium

Peter Neumann

Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts University and Professor of Medicine, Tufts University of School of Medicine

Tomas Philipson

Daniel Levin Professor of Public Policy, Irving B. Harris Graduate School of Public Policy, The University of Chicago

Rajesh Ranganathan

Vice President, Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Morgan Romine

Research Associate, Center for Health Policy, The Brookings Institution

Janet Woodcock

Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Marta Wosinska

Director, Economics Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration